Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

Inclusion Criteria: * Patients with ALL de novo or in relapse or refractory * Eligible to a chemotherapy treatment including L-asparaginase * Known contraindication and/or at risk of toxicity to other L-asparaginase formulation according to investigator opinion based on information available * Patient under 55 years old * Patient informed and consent provided (the 2 parents need to consent for children). Exclusion Criteria: * Patient unable to receive GRASPA due to general or visceral conditions * Serum creatinine ≥ 2 x ULN unless related to ALL * ALT or AST ≥ 3 x ULN unless related to ALL * Active clinical pancreatitis any grade or pancreatic enzyme elevation ≥ 1.5 ULN * Other serious conditions according to investigator's opinion. * Absence of documented serological test for HIV, B and C hepatitis * History of grade 3 transfusional incident or any contraindication to receive blood transfusion * Patient under concomitant treatment likely to cause hemolysis * Presence of specific anti-erythrocyte antibodies preventing from getting a compatible erythrocyte concentrate for the patient. * Patient undergoing yellow fever vaccination. * Patient under phenytoin treatment. * Women of childbearing potential without effective contraception as well as pregnant or breast feeding women. * Patient already included in another clinical trial